Cambridge, MA-based Genzyme (NASDAQ: [[ticker:GENZ]]) and Medicines for Malaria Venture, a nonprofit organization, said today they have formed a malaria drug collaboration with India-based Advinus Therapeutics. The organizations will work to develop new treatments for pregnant women and infants who are most threatened by the infection. The partners, which includes the Broad Institute of MIT and Harvard, will work to identify compounds active against key enzymes that help the malaria parasite survive.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
